Disease relevance of PSG3

• In general, individuals with satisfactory amelioration of sleep-disordered breathing on PSG 2 demonstrated similar improvement on PSG 3 [1].

High impact information on PSG3

• Since neither neuraminidase- nor endoglycopeptidase F-treatment of GPIIIa had any significant effect on the binding of PSG3, this array must be located within the amino acid sequence of GPIIIa but not in the carbohydrate moiety [2].
• PSG3 inhibited platelet aggregation induced by either ADP or collagen, it also inhibited fibrinogen binding to activated platelets in a dose-dependent fashion [2].
• PSG3, however, did not inhibit the binding of GRGDSP peptide to activated platelets [2].
• PSG3 bound also to certain polyanionic substances, such as double-stranded DNA, heparan sulfate, dextran sulfate and acetylated-LDL, but not to other polyanionic substances [2].
• These results suggest that PSG1 and PSG3 exhibit embryotropic activity at different stages of development in the mouse model [3].

Anatomical context of PSG3

• Two-cell stage mouse embryos were co-cultured in a two-chamber system with CHO cells expressing either recombinant PSG1 (rPSG1) or PSG3 (rPSG3) in the presence and absence of neutralizing PSG antibodies [3].

Associations of PSG3 with chemical compounds

• We identified an IgG anti-PL mAb, designated PSG3, which cross-reacted specifically with glycoprotein (GP) IIIa in human platelets and inhibited platelet aggregation [2].

Other interactions of PSG3

• SG5 is identical to PSG3, and SG9 to PSG1d, while SG8 most probably corresponds to PSG2 [4].
• The nadir of SaO2 during non-REM sleep was higher during PSG 3 than during PSG 1 (p = 0.002), but not different from that on PSG 2 [1].
• These results suggest that the PSG3 epitope on GPIIIa contains a particular array of negative charges, and possibly affects the fibrinogen binding to GPIIb/IIIa complex necessary for platelet aggregation [2].
• The other 17 sequences showed high similarity to known human genes (like PSG3, FN1, PAI-2) [5].

Analytical, diagnostic and therapeutic context of PSG3

• Patients who did not have a substantial improvement in the early postoperative period often had improvement on PSG 3, but there was a good deal of interindividual variability in this regard [1].

References